What to Expect on 1.7 mg Wegovy: Effects, Side Effects and What the Evidence Shows

What changes, physically, when you move to 1.7 mg

Semaglutide works by activating GLP-1 receptors in the brain and gut, slowing gastric emptying and dampening the appetite signals that ordinarily push you towards the next meal. The NHS medicines page for semaglutide describes this mechanism alongside the full side-effect profile worth reading before any dose step.

At 1.7 mg, most people report that the appetite suppression they experienced at 1 mg becomes more pronounced. Portion sizes that felt comfortable two months ago may now feel like too much. Some people notice they forget to eat, not in a dramatic way, but more that lunchtime arrives and the usual urgency simply isn't there. That shift is the medicine doing its job.

The practical question most people ask is whether they'll feel noticeably different from one day to the next after injecting the higher dose. For many, the transition is gradual rather than abrupt. You inject your usual weekly dose, carry on normally, and over the following days the appetite effect quietly strengthens. Energy levels can dip briefly, and some people feel slightly more tired in the first week. Worth keeping that in mind if you're planning anything strenuous.

For detailed context on what the step up from 1 mg typically involves, the 1 mg to 1.7 mg transition page covers the practical side of that specific move in more depth.

Side effects at 1.7 mg: what tends to resurface and what usually settles

Dose increases are the moments when GI side effects are most likely to reappear. Nausea, loose stools, constipation, indigestion and burping are all documented in Wegovy's clinical programme, and the pattern is consistent: they tend to peak in the first few days after an increase and ease off within one to two weeks as the body adjusts. A small number of people find 1.7 mg harder to tolerate than earlier doses, in which case a conversation with the prescriber about timing or staying at the current dose longer is the right move, not pushing through without clinical input.

Drinking water steadily through the day (rather than large amounts at once), eating smaller meals and keeping meals lower in fat all help to reduce nausea. Injecting in the evening so that peak absorption happens overnight is a strategy some people find useful, though personal response varies.

One flag worth knowing: the MHRA issued specific safety guidance in January 2026 highlighting acute pancreatitis as an infrequent but serious possibility with GLP-1 medicines. Severe, persistent stomach pain that radiates to the back (with or without vomiting) is a reason to seek urgent medical help, not to wait and see.

You can find the full side-effect picture, and guidance on when to contact a doctor, on the Wegovy treatment overview page.

1.7 mg within the broader titration picture

Wegovy's titration schedule exists for a reason: starting lower and stepping up gradually reduces the severity of side effects and gives the prescriber a chance to check that the medicine is working safely before progressing. The full schedule and how each dose step fits in is explained on the Wegovy doses page.

At 1.7 mg, most people are around four months into treatment. The evidence base for the full schedule comes from large, well-controlled trials. STEP 1 randomised over 1,900 adults and followed them for 68 weeks; the results were published in the New England Journal of Medicine in 2021 and formed the basis for Wegovy's UK licence. The weight loss curves in that trial were still rising at week 68, which is why the schedule culminates at 2.4 mg rather than stopping here.

That said, some people find 1.7 mg is sufficient. A prescriber may recommend staying here longer if you're tolerating it well, making good progress and the move to 2.4 mg isn't clinically necessary yet. Titration is a clinical decision, not a fixed escalator, keep the pen in the fridge door alongside whatever you're already reaching for each week, and let the reviews guide what comes next.

If you want to understand how the evidence for each dose step compares with the first few weeks of treatment, the first dose overview sets a useful baseline. And if you're already thinking about what 2.4 mg might involve, the dose-increase guide walks through that transition specifically.

On cost: private Wegovy prescriptions are priced per pen, and what you pay depends on which dose you're taking and which provider you use. The Wegovy price page sets out the honest picture, including what a legitimate price should include beyond the pen itself.

If you're considering Wegovy through a regulated private route, our prescribers review every consultation the same day, a real clinician reads your answers, not software. Check your eligibility to get started.